Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Asset Writedowns and Impairment (2019 - 2025)

Historic Asset Writedowns and Impairment for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $72000.0.

  • Pulmonx's Asset Writedowns and Impairment changed N/A to $72000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$24000.0, marking a year-over-year decrease of 10182.93%. This contributed to the annual value of $1.7 million for FY2024, which is 23865.88% up from last year.
  • Per Pulmonx's latest filing, its Asset Writedowns and Impairment stood at $72000.0 for Q3 2025.
  • Pulmonx's 5-year Asset Writedowns and Impairment high stood at $1.6 million for Q2 2024, and its period low was -$405000.0 during Q4 2023.
  • For the 5-year period, Pulmonx's Asset Writedowns and Impairment averaged around $227705.9, with its median value being $170000.0 (2022).
  • In the last 5 years, Pulmonx's Asset Writedowns and Impairment plummeted by 33823.53% in 2023 and then surged by 135233.64% in 2024.
  • Pulmonx's Asset Writedowns and Impairment (Quarter) stood at $214000.0 in 2021, then decreased by 20.56% to $170000.0 in 2022, then plummeted by 338.24% to -$405000.0 in 2023, then soared by 483.7% to $1.6 million in 2024, then crashed by 95.37% to $72000.0 in 2025.
  • Its Asset Writedowns and Impairment stands at $72000.0 for Q3 2025, versus -$50000.0 for Q2 2025 and -$46000.0 for Q1 2025.